12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
about
HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting AntiviralsDaclatasvir: A Review in Chronic Hepatitis C.Highly Successful Hepatitis C Virus (HCV) Treatment Outcomes in Human Immunodeficiency Virus/HCV-Coinfected Patients at a Large, Urban, Ryan White Clinic.Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era.Hepatitis C virus genotype 4: Genotype 1's little brother.Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.Advances in the treatment of HIV/HCV coinfection in adults.Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients.Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.Development of a Robust UPLC Method for Simultaneous Determination of a Novel Combination of Sofosbuvir and Daclatasvir in Human Plasma:2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
P2860
Q28073489-F696A9AB-1261-4D34-AF50-FD3CEAC2DC80Q30392100-E44E395B-8D90-4916-8B8E-99367E1A0745Q33647154-BD8B73F1-2D2F-4934-ADF6-B2306657527DQ38753617-0933D651-0B97-456E-9D8D-7DC646173D0BQ39025320-3C95EB17-DF2E-417B-AAC8-E562052A20CDQ40494843-31785065-4224-4DE3-9343-37AC6B7A37EAQ46445455-FF433040-2DD3-470C-B558-5C0C2C11A50DQ47291511-102C89D8-8F96-40E4-B76A-D1EDD13F240EQ47555039-367551B7-2D2A-4F8E-B965-1720699A8B72Q50262252-1E0FD967-7E3F-489A-BF51-A4CC7210FE02Q55027157-B6ED4CE2-202B-4192-9E85-795782A8A612Q58699240-F8CD4418-459A-4F83-8497-16380B629270Q58788714-C6286531-2A0B-46D6-82D8-8ABF6859C3D3
P2860
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
12 Weeks of Daclatasvir in Com ...... ation Antiretroviral Regimens.
@en
type
label
12 Weeks of Daclatasvir in Com ...... ation Antiretroviral Regimens.
@en
prefLabel
12 Weeks of Daclatasvir in Com ...... ation Antiretroviral Regimens.
@en
P2093
P2860
P356
P1476
12 Weeks of Daclatasvir in Com ...... ation Antiretroviral Regimens.
@en
P2093
Cheryl McDonald
Moti Ramgopal
Peter Ackerman
Rafia Bhore
Stephanie Noviello
P2860
P304
P356
10.1093/CID/CIW163
P407
P577
2016-03-29T00:00:00Z